Urvi Shah
Assistant Attending, Myeloma Service
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (31)
Year:
2026
Year:
2026
Year:
2026
The IMS and IMWG recently published a new consensus genomic staging (CGS) for defining high-risk (HR) newly diagnosed multiple myeloma (NDMM) patients, intended to provide consistency in clinical trial reporting and for use in designing enrichment clinical trials focused on the HR subset. The HR definition is the first to include TP53 mutations and considers the co-occurrence of IgH translocations with chromosome 1 aberrations. Given that limited data from the anti-CD38 monoclonal antibody-based quadruplet induction regimens were available for consensus consideration, here, we demonstrate that the new HR definition also predicts clinical outcomes in this setting. The patient population was 503 NDMM patients treated with daratumumab-based quadruplet induction therapy at Memorial Sloan Kettering Cancer Center, with a median follow-up time of 2.2 years, (maximum 7.9 years). The CGS criteria defined 31% of patients as HR, better delineating patients at intermediate risk by pre-existing prognostic scores. The CGS did not predict early minimal-residual disease (MRD) status, with MRD-negativity occurring at the same rate in HR and standard risk (SR) patients. However, the CGS did predict progression-free survival (PFS), which was a median of 2.6 years in HR compared with not reached in SR (p<0.0001). CGS risk remained predictive of PFS even in the setting of MRD-negativity following autologous stem cell transplantation. We conclude that while the IMS-IMWG CGS is ideal for standardizing NDMM trial design, any MRD-guided trial design should also consider genomic risk.
Year:
2026
Year:
2026
Clonal hematopoiesis of indeterminate potential, myelodysplastic syndromes, and acute myeloid leukemia are myeloid cell disorders that exist on a spectrum. Modifiable risk factors, including obesity, insulin resistance, physical activity, dietary patterns, smoking, and the microbiome, have been implicated in myeloid cell disorder pathogenesis. Although the connection between these modifiable risk factors and their association with myeloid disorders has been studied, as of September 2025, no clinical trials are ongoing that evaluate whether lifestyle interventions can alter myeloid disorder disease progression. This article reviews myeloid disorders and their association with inflammation and how lifestyle interventions may influence disease progression. Significance: Myeloid disorders are associated with inflammation and metabolic disorders such as obesity and diabetes mellitus. Dietary and lifestyle modifications may directly influence the pathogenesis, development, and survival by addressing inflammatory and metabolic pathways. However, additional preclinical research and large prospective clinical trials are needed to confirm these findings. This review provides an overview on myeloid disorder pathogenesis and modifiable factors that influence it, which may guide future research to reduce the myeloid disorder burden and improve outcomes for patients with clonal hematopoiesis of indeterminate potential, myelodysplastic syndromes, and acute myeloid leukemia.
Year:
2026
Background: Cytokine release syndrome (CRS) is one of the most common adverse effects of T-cell engaging bispecific antibodies (T-BsAbs) during the step-up dosing (SUD) phase of treatment. Previous studies demonstrated that a single prophylactic tocilizumab (Toci) dose of 8 mg/kg mitigated the incidence CRS events. Herein, we evaluated the efficacy of a low Toci dose (Toci-lo) of 4 mg/kg for CRS prophylaxis during the SUD phase.Methods: The study included relapsed/refractory multiple myeloma patients, treated with T-BsAbs and received prophylactic Toci-lo (cohort 1) administered prior to the first SUD only. A historical patient cohort that did not receive Toci prophylaxis was identified (cohort 2) for comparison. The CRS rates were compared between the two cohorts using the Fisher’s exact/Chi-square test. Univariate/multivariate logistic regression analysis was performed to estimate the odds of CRS events with Toci-lo prophylaxis.Results: A total of ninety patients were included in the final analysis (56 in cohort 1 and 34 in cohort 2). CRS rate was significantly lower in cohort 1 (21%, 95% CI:10.7-37.8%) compared to cohort 2 (55%, 95% CI: 38.0-70.8%; p=0.009). Grade 2 CRS rates were 2% and 21% in cohorts 1 and 2, respectively (p=0.0041). Based on multivariate logistic regression, Toci-low was associated with a significant reduction in CRS rates (OR: 0.2, 95% CI: 0.06-0.65; adjusted p=0.01).Conclusion: Based on our findings, prophylactic Toci-lo proved to be effective in reducing CRS events during the SUD phase of treatment with T-BsAbs. The implementation of this prophylactic strategy in clinical practice might minimize healthcare expenditures.
Year:
2026
PURPOSE CNS involvement in North American adult T-cell leukemia/lymphoma (NA-ATLL) remains poorly understood. This study examined the CNS involvement in patients with ATLL treated at a tertiary hospital in New York City. METHODS CNS involvement was defined by positive cerebrospinal fluid (CSF) cytology, flow cytometry, positive CNS imaging, or neurological examination findings. RESULTS Among 94 patients with NA-ATLL, 21 (22.3%) had CNS involvement. CSF was involved in 13 patients at diagnosis and five at relapse. Magnetic resonance imaging detected brain and spinal involvement in 24% and 14% of the patients, respectively. Results of neurological examinations were abnormal in 33% and 14% of the patients at diagnosis and relapse, respectively. The XPO1 E571K mutation was found in two patients with extensive, treatment-refractory CNS disease, with a median overall survival (OS) of 2 months. Other mutations, including KLF2 and PI3KCD , were noted in two patients. The median OS was 8.5 months, and the median relapse-free survival (RFS) was 6.5 months in our series. In most cases (5/21), the lymphomatous phenotype appeared to have a direct mass-like extension, whereas in patients with predominant blood involvement tended to spread to the CSF by traversing the blood-brain barrier. CONCLUSION In this report, we describe the patterns of CNS involvement in ATLL and their association with mutations. We also describe two rapidly fatal cases with the XPO1 E571K mutation, which may represent a novel therapeutic target for T-cell lymphomas.
Year:
2025
Year:
2025
Consumption of a Western diet and high body mass index (BMI) are risk factors for progression from premalignant phenotypes to multiple myeloma, a hematologic cancer. In the NUTRIVENTION trial (NCT04920084), we administered a high-fiber, plant-based diet (HFPBD; meals for 12 weeks, coaching for 24 weeks) to 23 participants with myeloma precursor states and elevated BMI. The intervention was feasible and improved quality of life and modifiable risk factors: metabolic (BMI, insulin resistance), microbiome (diversity, composition), and immune (inflammation, monocyte subsets). Disease progression trajectory improved (n = 2) or was stable. Findings were translated to Vk*MYC mice modeling the myeloma precursor state, in which a high-fiber diet (HFD) delayed disease progression through improved metabolism and microbiome composition, leading to increased short-chain fatty acid production that reinvigorated antitumor immunity and inhibited tumor growth. These effects from fiber consumption were independent of calorie restriction and weight loss. A HFD is a low-risk intervention that may delay progression to myeloma. Significance: A HFPBD in participants with precursor plasma cell disorders and an elevated BMI improved metabolic, microbiome, and immune biomarkers of disease. In a subset, it may delay progression to myeloma. In mouse models, a HFD delayed progression to myeloma independent of calorie restriction.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (30)
Ana Acuna-Villaorduna
Assistant Professor
Icahn School of Medicine at Mount Sinai
Thomas Christian Wiemers
Leipzig University
Andriy Derkach
Associate Attending Biostatistician
Memorial Sloan Kettering Cancer Center
Matthew Pianko
Clinical Associate Professor
University of Michigan
Fiona Malcomson
Lecturer in Human Nutrition
Newcastle University
Justin Cross
Sloan Kettering Institute
Diego Adrianzen Herrera
Associate Professor
University of Vermont College of Medicine
Ola Landgren
Professor of Medicine
Sylvester Comprehensive Cancer Center, University of Miami
Sergio Giralt
Chief Attending, Adult BMT Service
Memorial Sloan Kettering Cancer Center
Kah Poh Loh
University of Rochester Medical Center
Eileen White
Chief Scientific Officer
Rutgers Cancer Institute of New Jersey
Kira Gritsman
Associate Professor
Albert Einstein College of Medicine
Gunjan Shah
Memorial Sloan Kettering Cancer Center
Catherine Marinac
Harvard University
Gladys Block
University of California, Berkeley
Joseph Deasy
Professor of Medical Physics
Weill Cornell Medicine
Jonathan Peled
Director
Memorial Sloan Kettering Cancer Center
Mihir Maheshkumar Shah
Chief, Surgical Oncology
Emory University
Saad Usmani
Chief Attending
Memorial Sloan Kettering Cancer Center
Marcus Goncalves
Associate Professor
NYU Langone Health
Bihui Ye
Professor
Albert Einstein College of Medicine
Sridevi Rajeeve
Memorial Sloan Kettering Cancer Center
Ed Reznik
Sloan Kettering Institute
Anita D'Souza
Medical College of Wisconsin
Astha Thakkar
University of North Carolina
Hamza Hashmi
Memorial Sloan Kettering Cancer Center
Francesco Maura
Assistant Professor
Sylvester Comprehensive Cancer Center
Juan-José Garcés
Research Scholar
Sloan Kettering Institute
Tina Skinner
Professor and Discipline Lead of Exercise Science and Exercise Physiology
University of New South Wales
William D Figg
Senior Investigator, Lab Chief, Associate Director
National Institutes of Health
Make your next move.
Prepare your application
Review drafts before you send them.